PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma

Refractory Diffuse Large B-Cell Lymphoma Clinical Trial

Official title:

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Subjects With Relapsed or Refractory B Cell Non-Hodgkin's Lymphoma

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03488251
• Other study ID #: MT-3724_NHL_002
• Status: Terminated
• Phase: Phase 2
• Start date: August 20, 2018
• Est. completion date: March 12, 2021

Study information

• Verified date: July 2022
• Source: Molecular Templates, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and tolerability of MT-3724 in combination with gemcitabine and oxaliplatin (GEMOX) in participants with relapsed or refractory B-Cell NHL.

Description:

This is a multi-center, open-label two-part study evaluating the safety and tolerability of MT-3724 in combination with GEMOX in relapsed or refractory B-cell Lymphoma patients. Part 1: (MT-3724 Dose Escalation) Define the maximum tolerated dose (MTD) of MT-3724 in combination with standard treatment of GEMOX Part 2: (MTD Expansion Cohort) Confirm the safety and tolerability of the MTD of MT-3724 from Part 1 in the MTD Expansion Cohort, where MT-3724 will be given at the MTD in combination with GEMOX. In addition, the PK, PD, immunogenicity and tumor response at the MTD of MT-3724 in combination with GEMOX will be more thoroughly evaluated in Part 2. In original protocol and amendment 2, participants will be administered intravenous (IV) MT-3724 over 1 hour on Days 1, 3, 5, 8, 10 and 12 in Cycles 1 and 2 (each 28-day cycle) and on Days 1, 8, 15, and 22 in Cycles 3 and 4 (each 28-day cycle). Participants will also be administered Gemcitabine 1000 milligrams per meter square (mg/m^2) as 30-minute IV infusion and Oxaliplatin 100 mg/m^2 as 2-hour IV infusion on Days 2 and 16 in Cycles 1, 2, 3 and 4 (each 28-day cycle). Per amendment 2, participants will be administered MT-3724 on Days 1, 3, 5, 8, 10, 12, 15, 22, 29, and 36 in Cycle 1 (42-day cycle). In Cycles 2, 3 and 4, MT-3724 will be administered weekly on Days 1, 8, 15, and 22 of each 28-day cycle. Gemcitabine and oxaliplatin will be administered on Days 16 and 30 of Cycle 1 and on Days 2 and 16 in Cycles 2, 3 and 4 (42-day cycle for Cycle 1 and 28-day cycle for Cycle 2, Cycle 3 and Cycle 4). Continued Treatment with MT-3724 in combination with GEMOX will continue for four cycles of until death, disease progression, unacceptable toxicity, withdrawal of consent or another reason for withdrawal. After four cycles, the participants who experience clinical benefit can continue MT-3724 treatment with additional cycles of 28 days each (either alone or in combination with GEMOX) if supported by the investigator's assessment of the benefit-risk ratio, after consultation with sponsor and Medical Monitor

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 8
• Est. completion date: March 12, 2021
• Est. primary completion date: March 12, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Be adequately informed about the study and fully consent to participation as demonstrated by signing the written informed consent form before any screening procedure.

2. Be aged =18 years on the date of signing the informed consent form.

3. Have relapsed or refractory B-cell NHL that, in the investigator's opinion, could benefit from MT-3724+GEMOX therapy. At least one histologically documented relapse of

NHL, by:

1. Bone marrow biopsy (FNA is not acceptable) or

2. Excisional lymph node biopsy or

3. Core biopsy of any involved organ (FNA not acceptable)

4. CD20-positive histology must have been confirmed at any time during NHL disease course and documented in the medical history

5. If no histology is available after any relapse the investigator can consult the medical monitor to discuss if the patient can be included

4. All subtypes of B-cell NHL may be considered for Part 1 (MT-3724 dose escalation). Only histologically documented DLBCL (including mixed histology) may be considered for Part 2 (expansion cohort).

5. Have received all approved therapies for NHL that are applicable for the patient in the opinion of the treating physician.

1. Patients refractory to treatment are eligible.

2. Patient who have progressed following CAR T-cell therapy are also eligible.

6. Have measurable disease by Lugano Classification for NHL

1. >1.5 cm longest diameter (LDi) for lymph nodes

2. >1 cm LDi for extranodal disease

7. Have ECOG performance score of =2.

8. Have adequate bone marrow function, as determined by:

1. Absolute neutrophil count (ANC) =1,000/mm3 and

2. Platelet count =50,000 mm³

9. Have adequate kidney function, assessed by thecreatinine clearance (CLcr) to be = 50 mL/min either measured or estimated using the Cockcroft-Gault formula. . a. At the investigator's discretion,calculated estimated CLcr of < 50mL/min may be verified eGFR based on the 24-hour urine collection. Subjects with GFR =50 mL/min will be eligible irrespective of the estimated CLcr result.

10. Have adequate hepatic function, as determined by:

1. Total bilirubin =1.5 x ULN, or =3 x ULN for subjects with Gilbert's Syndrome and

2. Aspartate aminotransferase (AST) =3 x ULN (or = 5.0 x ULN if liver involvement) and

3. Alanine aminotransferase (ALT) =3 x ULN (or = 5.0 x ULN if liver involvement).

11. Have adequate coagulation, as determined by:

1. INR or PT =1.5 x ULN

2. aPTT =1.5 x ULN

12. Have adequate serum albumin, as determined by:

a. Albumin = 3.0 g/dL

13. Women of reproductive potential must have a negative pregnancy test during the screening period within 72 hours before the start of treatment. Women not of reproductive potential are female subjects who are postmenopausal or permanently sterilized (e.g., tubal occlusion, hysterectomy,bilateral salpingectomy).

14. Subjects of reproductive potential and their partners must agree to either to abstain continuously from heterosexual intercourse or to use a reliable birth control method between signing the informed consent until 6 months following the last dose of MT-3724 or GEMOX . The investigator or a designated associate should advise the subject how to achieve adequate contraception. The following birth control methods may be considered as adequate

1. Condoms (male or female) with or without a spermicidal agent;

2. Diaphragm or cervical cap with spermicide;

3. Intrauterine device;

4. Hormone-based contraception: Established use of oral, injected, or implanted hormonal methods of contraception;

5. True abstinence;

6. Vasectomy is an acceptable method for a male subject or male partner of a female subject.

Exclusion criteria:

1. History or current evidence of neoplastic disease that is histologically distinct from NHL except cervical carcinoma in situ, superficial noninvasive bladder tumors, curatively treated Stage I-II non-melanoma skin cancer, or any other previous cancer curatively treated >2 years before the start of treatment.

2. Current evidence of new or growing brain or spinal metastases during screening.

3. History of allogeneic hematopoietic stem cell transplant within 180 days before the start of treatment.

4. Current evidence of acute or chronic Graft versus Host Disease.

5. Current evidence of CTCAE Grade >1 toxicity (except for hair loss, and those toxicities

6. Current evidence of incomplete recovery from surgery before the start of treatment, or planned surgery at any time during the study until the EoT Visit, except minor elective interventions deemed acceptable by the investigator.

7. History or current evidence of significant (CTCAE Grade =2) infection or wound within 4 weeks before the start of treatment.

8. Patients with uncontrolled or severe cardiovascular disease, including myocardial infarct or unstable angina within 6 months prior to start of study treatment, New York Heart Association (NYHA) Class II or greater congestive heart failure, serious arrhythmias requiring medication for treatment, clinically significant pericardial disease, or cardiac amyloidosis may not be enrolled.

9. Patients with a known history of drug abuse or any chronic neurologic, psychiatric, endocrine, metabolic, immunologic, hepatic or renal disease (including a history of hemolytic uremic syndrome) that in the opinion of the Investigator would adversely affect study participation.

10. Patients with known active Hepatitis C, HIV or a present history of Hepatitis B

11. Women who are pregnant or breastfeeding

12. History or current evidence of hypersensitivity to any study drugs, or current evidence of hypersensitivity requiring systemic steroid doses =20 mg/day Prednisone equivalent

13. Received any amount of anti-CD20 MAb therapy within the following periods before the start of treatment

1. Rituximab (Rituxan®): 84 days; if a subject had received rituximab within 37 Weeks before the start of treatment, then a serum rituximab level must be negative (<500 ng/mL) at the screening period

2. Obinutuzumab (Gazyva®): 184 days

3. Ofatumumab (Arzerra®): 88 days

14. Received therapy for NHL (except anti-CD20 Mab listed above) within 4 weeks before the start of treatment

15. Any investigational drug treatment from 4 weeks or 5 half-lives of the agent before the start of treatment, whichever is longer, until the EoT Visit

16. Received radiotherapy to tumor lesions that would be chosen as target lesions (measurable disease) within 4 weeks before the start of treatment, unless the lesion exhibited objective progression between the radiotherapy and the screening according to the Lugano Classification for NHL. a. Palliative radiotherapy to non-target lesions is allowed at the investigator's discretion after consultation with the Medical Monitor and sponsor.

17. Received any vaccines within 28 days of the start of treatment, or likely to require vaccines at any time from the start of treatment until 28 days after the last dose of MT-3724. Injectable flu vaccine (inactivated or recombinant) is permitted at the investigator's discretion

18. Received systemic immune modulators within 2 weeks before the start of treatment including but not limited to systemic corticosteroids >20 mg/day of prednisone equivalent, cyclosporine and tacrolimus. Corticosteroids for pre-medication and NSAIDs are permitted.

19. Received any investigational drug treatment within 4 weeks or within 5 half-lives of the therapeutic agent before the start of treatment, whichever is longer, until EoT Visit

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, B-Cell
• Lymphoma, Large B-Cell, Diffuse
• Lymphoma, Non-Hodgkin
• Non-hodgkin Lymphoma,B Cell
• Refractory Diffuse Large B-Cell Lymphoma
• Relapsed Diffuse Large B-Cell Lymphoma

Intervention

Drug:
• MT-3724
MT-3724 will be administered.
• Gemcitabine
Gemcitabine will be administered.
• Oxaliplatin
Oxaliplatin will be administered.

Locations

Country	Name	City	State
United States	University of Maryland Greenebaum Comprehensive Cancer Center	Baltimore	Maryland
United States	Rush University	Chicago	Illinois
United States	Good Samaritan Hospital	Cincinnati	Ohio
United States	UT Southwestern Medical Center Clinical Research	Dallas	Texas
United States	Duke Cancer Center	Durham	North Carolina
United States	Indiana Blood and Marrow Transplantation	Indianapolis	Indiana
United States	UC Irvine Health / Chao Family Comprehensive Cancer Center	Orange	California
United States	Sarcoma Oncology	Santa Monica	California
United States	Innovative Clinical Research Institute	Whittier	California

Sponsors (1)

Lead Sponsor	Collaborator
Molecular Templates, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Part 1 and 2: Number of Participants With Dose Limiting Toxicities (DLTs)	A DLT is any treatment-emergent adverse event (TEAE) that occurred after the start of infusion in cycle 1 of Part 1 and the TEAE is at least possibly related to the study drug, as determined by the sponsor after consultation with the investigator(s).	Up to 168 Days
Primary	Part 1 and 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)	An AE is as any untoward medical occurrence in a participant or clinical investigation in a participant administered a pharmaceutical product(s) and which does not necessarily have to have a causal relationship with this experimental intervention(s). A SAE is any AE that is fatal or life-threatening, permanently disabling (incapacitating or interfering with the ability to resume usual life patterns), results in unplanned in-subject hospitalization or prolongation of an existing hospitalization, results in a congenital abnormality or birth defect, or any other situation that require medical or scientific judgement. Number of participants with common >=0 percent (%) TEAEs and SAEs are presented.	Up to 168 Days
Secondary	Part 1 and 2: Maximum Concentration (Cmax) Following Administration of MT-3724	Blood samples were planned to be collected at indicated time points for pharmacokinetic (PK) analysis of MT-3724. PK Population consisted of all participants who received at least one dose of MT-3724 and have at least one post-Baseline PK value.	Cycle(C)1:Day1:Predose,10 minutes(min) before end of treatment(EOT),5,30 min,1,2,3,4 hours after EOT,Days5,12:Predose,10 min before EOT,5min,2hours after EOT;C2,C3,C4:Day1:Predose,10min before EOT,5 min after EOT(C1 is 42-days;C2,C3,C4 are 28-days cycles)
Secondary	Part 1 and 2: Area Under the Plasma Concentration Time Curve (AUC) Following Administration of MT-3724	Blood samples were planned to be collected at indicated time points for PK analysis of MT-3724.	Cycle(C)1:Day1:Predose,10 minutes(min) before end of treatment(EOT),5,30 min,1,2,3,4 hours after EOT,Days5,12:Predose,10 min before EOT,5min,2hours after EOT;C2,C3,C4:Day1:Predose,10min before EOT,5 min after EOT(C1 is 42-days;C2,C3,C4 are 28-days cycles)
Secondary	Part 1 and 2: Time to Maximum Plasma Concentration (Tmax) Following Administration of MT-3724	Blood samples were planned to be collected at indicated time points for PK analysis of MT-3724.	Cycle(C)1:Day1:Predose,10 minutes(min) before end of treatment(EOT),5,30 min,1,2,3,4 hours after EOT,Days5,12:Predose,10 min before EOT,5min,2hours after EOT;C2,C3,C4:Day1:Predose,10min before EOT,5 min after EOT(C1 is 42-days;C2,C3,C4 are 28-days cycles)
Secondary	Part 1 and 2: Number of Participants With Immunophenotyping Data Outside the Reference Range	Blood samples were planned to be collected at indicated time points for analysis of immunophenotyping parameters which included cluster of differentiation (CD)3 (Percentage [%] and absolute), CD4 (% and absolute), CD8 (% and absolute), CD4:CD8 ratio, CD19 (% and absolute), Natural Killer (NK) cells (% and absolute), naïve B cells (% and absolute), non-switched memory B cells (% and absolute), class-switched memory B cells, Immunoglobulin (Ig)M only memory B cells (% and absolute), and total memory B cells (% and absolute).	Up to 168 Days
Secondary	Part 1 and 2: Number of Participants With Anti-drug Antibody Titer	Blood samples were planned to be collected at indicated time points for analysis of anti-drug antibody titer.	Up to 168 Days
Secondary	Part 1 and 2: Number of Participants With Positive Neutralizing Antibodies	Blood samples were planned to be collected at indicated time points for analysis of positive neutralizing antibodies.	Up to 168 Days
Secondary	Part 1 and 2: Objective Response Rate	Objective response rate is defined as the participants with a reduction in tumor size (Partial Response [PR] or Complete Response [CR]) using the Lugano Classification for Lymphoma, adjusted according to Lymphoma response to immunomodulatory therapy criteria (LYRIC).	Up to 168 Days
Secondary	Part 1 and 2: Disease Control Rate	Disease Control rate is defined as participants with objective response of CR, PR or stable disease (SD) defined as SD for 3 months or longer from the Baseline scan.	Up to 168 Days
Secondary	Part 1 and 2: Duration of Response	Duration of Response is defined as the time from first documented stable disease to the actual date of disease progression or death, for participants who met the criteria of having stable disease for at least 3 months from Baseline. Data was not collected due to early termination of the trial.	Up to 168 Days
Secondary	Part 1 and 2: Progression-free Survival	Progression-Free Survival is defined as the time from the start of treatment with MT-3724 on Cycle 1 Day 1 to the date of disease progression or death from any cause. Data was not collected due to early termination of the trial.	Up to 168 Days